Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP1 | P24666 | 13/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | RAD52 | P43351 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | TERT | O14746 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3875233 | 0.94 | ACP1 (0.68) | ACP1KDM4ENPC1LMNAGLA | |
| SCHEMBL3864574 | 0.84 | ACP1 (0.54) | ACP1TERT | |
| SCHEMBL3870377 | 0.78 | ACP1 (0.54) | ACP1LMNAKMT2AMAPK1PDE10A | |
| SCHEMBL3865437 | 0.77 | PDE10A (0.43) | ACP1PDE10A | |
| SCHEMBL3870114 | 0.76 | METAP1 (0.58) | KDM4ENPC1LMNAPOLBGAA | |
| SCHEMBL3878115 | 0.76 | ACP1 (0.52) | ACP1POLBRAD52RAB9AKMT2A | |
| SCHEMBL17651549 | 0.76 | ACP1 (1.00) | ACP1LMNAKMT2APDE10A | |
| SCHEMBL30457841 | 0.76 | ACP1 (1.00) | ACP1LMNAKMT2APDE10A | |
| SCHEMBL23015141 | 0.76 | ACP1 (0.82) | ACP1KDM4EPOLB | |
| SCHEMBL29636831 | 0.76 | ACP1 (0.82) | ACP1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572914-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-11 | — | — | US | claimed |
| EP-1694686-A1 | KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2006-08-30 | — | — | EP | claimed |
| US-20050153966-A1 | Kinase inhibitors | SYRRX, INC. | 2005-07-14 | — | — | US | claimed |
| WO-2005061519-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2005-07-07 | — | — | WO | claimed |
| US-7572914-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-11 | — | — | US | disclosed |
| US-7572914-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-11 | — | — | US | disclosed |
| EP-1694686-A1 | KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2006-08-30 | — | — | EP | disclosed |
| US-20050153966-A1 | Kinase inhibitors | SYRRX, INC. | 2005-07-14 | — | — | US | disclosed |
| WO-2005061519-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153966-A1 | Kinase inhibitors | MAP3K1, MAP3K20, MAP3K2 | ACP1 296/4885KDM4E 1076/4885NPC1 3485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.